15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Programmed death ligand 1 (PD-L1) is highly expressed in many cancers. We investigated the expression of PD-L1 and its relationship with vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 and KI-67 expression in 64 patients with primary glioma. The expression rate of PD-L1 in glioma patients was 78.12%. PD-L1 levels correlated with the tumor grade ( p = 0.013), VEGF status ( p = 0.002) and KI-67 status ( p = 0.002). In addition, PD-L1 levels correlated positively with VEGF ( r = 0.314, p = 0.011) and KI-67 ( r = 0.391, p = 0.001) levels when the data were treated as continuous variables. This is the first report suggesting that PD-L1 is important for glioma angiogenesis and proliferation. Thus, further research should be conducted to assess the combination of targeted VEGF therapy and anti-PD-L1 immunotherapy for the treatment of glioma.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

          Suppression of dendritic cell function in cancer patients is thought to contribute to the inhibition of immune responses and disease progression. Molecular mechanisms of this suppression remain elusive, however. Here, we show that a fraction of blood monocyte-derived myeloid dendritic cells (MDCs) express B7-H1, a member of the B7 family, on the cell surface. B7-H1 could be further upregulated by tumor environmental factors. Consistent with this finding, virtually all MDCs isolated from the tissues or draining lymph nodes of ovarian carcinomas express B7-H1. Blockade of B7-H1 enhanced MDC-mediated T-cell activation and was accompanied by downregulation of T-cell interleukin (IL)-10 and upregulation of IL-2 and interferon (IFN)-gamma. T cells conditioned with the B7-H1-blocked MDCs had a more potent ability to inhibit autologous human ovarian carcinoma growth in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. Therefore, upregulation of B7-H1 on MDCs in the tumor microenvironment downregulates T-cell immunity. Blockade of B7-H1 represents one approach for cancer immunotherapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            PD-L1 expression and prognostic impact in glioblastoma.

            Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At issue is the validation of PD-L1 biomarker assays and prognostic impact.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

              Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in some patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other tumor types. About 20 % of advanced NSCLC patients and 30 % of advanced melanoma patients experience tumor responses from checkpoint blockade monotherapy, with better clinical responses seen with the combination of anti-PD-1 and anti-CTLA-4 antibodies. Given the power of these new therapies, it is important to understand the complex and dynamic nature of host immune responses and the regulation of additional molecules in the tumor microenvironment and normal organs in response to the checkpoint blockade therapies. In this era of precision oncology, there remains a largely unmet need to identify the patients who are most likely to benefit from immunotherapy, to optimize the monitoring assays for tumor-specific immune responses, to develop strategies to improve clinical efficacy, and to identify biomarkers so that immune-related adverse events can be avoided. At this time, PD-L1 immunohistochemistry (IHC) staining using 22C3 antibody is the only FDA-approved companion diagnostic for patients with NSCLC-treated pembrolizumab, but more are expected to come to market. We here summarize the current knowledge, clinical efficacy, potential immune biomarkers, and associated assays for immune checkpoint blockade therapies in advanced solid tumors.
                Bookmark

                Author and article information

                Journal
                Oncotarget
                Oncotarget
                Oncotarget
                ImpactJ
                Oncotarget
                Impact Journals LLC
                1949-2553
                25 July 2017
                17 May 2017
                : 8
                : 30
                : 49702-49712
                Affiliations
                1 School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China
                2 Shandong Academy of Medical Sciences, Jinan, Shandong, China
                3 Department of Radiation Oncology, Shandong Province Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
                4 Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China
                5 Department of Pathology, General Hospital of Jinan Military Command, Jinan, Shandong, China
                6 Department of Medicine, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
                7 Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
                8 Department of Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
                9 Department of Pathology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
                Author notes
                Correspondence to: Dianbin Mu, mudbin@ 123456163.com
                Article
                17922
                10.18632/oncotarget.17922
                5564800
                28591697
                827ead00-60d7-4189-84d3-e28627594cb0
                Copyright: © 2017 Xue et al.

                This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.

                History
                : 26 January 2017
                : 1 May 2017
                Categories
                Research Paper

                Oncology & Radiotherapy
                pd-l1,angiogenesis,proliferation,invasion,glioma
                Oncology & Radiotherapy
                pd-l1, angiogenesis, proliferation, invasion, glioma

                Comments

                Comment on this article